| Literature DB >> 34974656 |
Min-Jeong Lee1, Eunyoung Lee2,3,4, Bumhee Park2,3, Inwhee Park1.
Abstract
BACKGROUND: The limited literature on mental illness in end-stage kidney disease (ESKD) patients suggests that this disease is common and burdensome but underrecognized in clinical practice. This study aimed to analyze the prevalence of mental illness in ESKD patients.Entities:
Keywords: Anxiety; Chronic kidney failure; Depression; Mental disorders
Year: 2021 PMID: 34974656 PMCID: PMC8995483 DOI: 10.23876/j.krcp.21.047
Source DB: PubMed Journal: Kidney Res Clin Pract ISSN: 2211-9132
Figure 1.Flowchart of the study cohort.
ESKD, end-stage kidney disease; HD, hemodialysis; KT, kidney transplant; PD, peritoneal dialysis.
Baseline characteristics of the end-stage kidney disease cohort
| Characteristic | Overall (n = 70,079) | HD (n = 61,497) | KT (n = 3,901) | PD (n = 4,681) | p-value[ |
|---|---|---|---|---|---|
| Follow-up (yr) | 4.3 ± 2.4 | 4.2 ± 2.4 | 4.4 ± 2.3 | 4.5 ± 2.3 | <0.001 |
| Age at index date (yr) | 60.6 ± 14.2 | 62.1 ± 13.7 | 45.0 ± 11.7 | 53.9 ± 13.4 | <0.001 |
| 18–39 | 5,840 (8.3) | 3,876 (6.3) | 1,288 (33.0) | 676 (14.4) | <0.001 |
| 40–59 | 25,729 (36.7) | 21,115 (34.3) | 2,229 (57.1) | 2,385 (51.0) | |
| ≥60 | 38,510 (55.0) | 36,506 (59.4) | 384 (9.9) | 1,620 (34.6) | |
| Male sex | 41,777 (59.6) | 36,842 (59.9) | 2,291 (58.7) | 2,644 (56.5) | <0.001 |
| Comorbidity[ | |||||
| Diabetes | 46,649 (66.6) | 41,934 (68.2) | 1,814 (46.5) | 2,901 (62.0) | <0.001 |
| Hypertension | 64,299 (91.8) | 56,258 (91.5) | 3,722 (95.4) | 4,319 (92.3) | <0.001 |
| Cardiovascular | 18,085 (25.8) | 16,257 (26.4) | 639 (16.4) | 1,189 (25.4) | <0.001 |
| Cerebrovascular | 11,671 (16.7) | 10,961 (17.8) | 220 (5.6) | 490 (10.5) | <0.001 |
| Chronic lung disease | 15,937 (22.7) | 14,594 (23.7) | 594 (15.2) | 749 (16.0) | <0.001 |
| Chronic liver disease | 3,219 (4.6) | 2,956 (4.8) | 81 (2.1) | 182 (3.9) | <0.001 |
| Psychiatric disorder[ | |||||
| Depression | 2,181 (3.1) | 1,860 (3.0) | 151 (3.9) | 170 (3.6) | 0.001 |
| Anxiety | 3,064 (4.4) | 2,584 (4.2) | 258 (6.6) | 222 (4.7) | <0.001 |
| Somatoform/conversion disorder | 125 (0.2) | 98 (0.2) | 21 (0.5) | 6 (0.1) | <0.001 |
| Stress reaction/adjustment disorder | 477 (0.7) | 424 (0.7) | 24 (0.6) | 29 (0.6) | 0.75 |
| Substance abuse disorder | 133 (0.2) | 119 (0.2) | 6 (0.2) | 8 (0.2) | 0.82 |
Data are expressed as mean ± standard deviation or number (%).
HD, hemodialysis; KT, kidney transplant; PD, peritoneal dialysis.
p-value was based on the analysis of variance test; otherwise, the chi-square test was used.
Comorbidities and psychiatric disorders observed during the observation period, which was 1 year before initiation of renal replacement therapy to December 31, 2017.
Figure 2.Mental illnesses in end-stage kidney disease patients by kidney replacement therapy.
KRT, kidney replacement therapy; HD, hemodialysis; KT, kidney transplant; PD, peritoneal dialysis.
Figure 3.Frequency density of (A) all visits and (B) the first visit with mental illness by kidney replacement therapy in the end-stage kidney disease cohort.
KRT, kidney replacement therapy; HD, hemodialysis; KT, kidney transplant; PD, peritoneal dialysis.
Hazard ratios of mental illnesses from the multivariable Cox proportional hazards model in the end-stage kidney disease cohort (n = 70,079)
| Psychiatric disorder | Parameter | HR (95% CI) | p-value | |
|---|---|---|---|---|
| Depression | KRT | HD | 2.19 (1.95–2.46) | <0.001 |
| PD | 1.97 (1.73–2.26) | <0.001 | ||
| KT | Ref | |||
| Age group (yr) | 18–39 | Ref | ||
| 40–59 | 1.17 (1.09–1.26) | <0.001 | ||
| ≥60 | 1.27 (1.18–1.36) | <0.001 | ||
| Male sex | 1.17 (1.13–1.22) | <0.001 | ||
| Anxiety | KRT | HD | 1.64 (1.50–1.80) | <0.001 |
| PD | 1.22 (1.09–1.35) | 0.001 | ||
| KT | Ref | |||
| Age group (yr) | 18–39 | Ref | ||
| 40–59 | 1.11 (1.04–1.18) | 0.002 | ||
| ≥60 | 1.04 (0.98–1.11) | 0.23 | ||
| Male sex | 1.20 (1.16–1.24) | <0.001 | ||
| Somatoform/conversion disorder | KRT | HD | 0.96 (0.70–1.32) | 0.80 |
| PD | 0.60 (0.38–0.97) | 0.04 | ||
| KT | Ref | |||
| Age group (yr) | 18–39 | Ref | ||
| 40–59 | 0.98 (0.76–1.26) | 0.87 | ||
| ≥60 | 0.71 (0.54–0.92) | 0.01 | ||
| Male sex | 1.07 (0.91–1.26) | 0.42 | ||
| Stress reaction/adjustment disorder | KRT | HD | 1.67 (1.29–2.15) | <0.001 |
| PD | 0.99 (0.72–1.39) | 0.98 | ||
| KT | Ref | |||
| Age group (yr) | 18–39 | Ref | ||
| 40–59 | 0.99 (0.76–1.06) | 0.19 | ||
| ≥60 | 0.91 (0.77–1.08) | 0.28 | ||
| Male sex | 1.08 (0.98–1.19) | 0.11 | ||
| Substance abuse disorder | KRT | HD | 2.40 (1.31–4.38) | 0.004 |
| PD | 1.84 (0.90–3.77) | 0.10 | ||
| KT | Ref | |||
| Age group (yr) | 18–39 | Ref | ||
| 40–59 | 1.22 (0.86–1.73) | 0.28 | ||
| ≥60 | 0.83 (0.57–1.19) | 0.31 | ||
| Male sex | 3.30 (2.58–4.37) | <0.001 | ||
HR, hazard ratio; CI, confidence interval; HD, hemodialysis; KT, kidney transplant; KRT, kidney replacement therapy; PD, peritoneal dialysis; Ref, reference group.